Photoredox catalysis, peptide therapeutics, biologics, targets, drug discovery, Pharma, Pharma, Bloom, Steve Bloom, The Bloom Group, KU, Science, Peptides, research, unnatural amino acids, peptide libraries, biocompatible photocatalysts, tethering biomolecules, chemotherapeutics, photochemical strategies, fusion proteins, antibody conjugates, bi-specific peptides, light activated molecules, electron oxidation, synthetic radical intermediates, therapeutic scaffolds, medicinally relevant compounds, bio-derived therapeutics, small cell lung cancer, viral capsid, improved therapeutics,

THE BLOOM GROUP

TARGETS

Small Cell Lung Cancer: 

Lung cancer is one of the most prevalent forms of cancer worldwide. One type of lung cancer, small cell lung cancer, is particularly devastating affecting 30,000-35,000 people in the U.S. each year. The recurrence rate among small cell lung cancer patients is extremely high resulting in a two-year survival rate post treatment. To combat this problem, the Bloom lab seeks to employ photoredox catalysis to prepare novel peptides and bio-derived therapeutics to treat small cell lung cancer. These therapeutic alternatives focus on targeting the chemo-resistant tumor cells found in small cell lung cancer, thereby preventing tumor regrowth and eradicating the cancer.

Photoredox catalysis, peptide therapeutics, biologics, targets, drug discovery, Pharma, Pharma, Bloom, Steve Bloom, The Bloom Group, KU, Science, Peptides, research, unnatural amino acids, peptide libraries, biocompatible photocatalysts, tethering biomolecules, chemotherapeutics, photochemical strategies, fusion proteins, antibody conjugates, bi-specific peptides, light activated molecules, electron oxidation, synthetic radical intermediates, therapeutic scaffolds, medicinally relevant compounds, bio-derived therapeutics, small cell lung cancer, viral capsid, improved therapeutics,

Human Immunodeficiency Virus Type 1:

Human Immunodeficiency Virus (HIV) affects over 35 million people worldwide. HIV-1, the primary form of HIV, accounts for 95% of all HIV cases. Accordingly, an enormous effort to understand and treat HIV-1 has been made in recent years. Work by several laboratories have revealed that the nucleocapsid protein, NCp7, plays a pivotal role in binding to viral RNA and inducing the formation of the viral capsid. The recognition between NCp7 and viral RNA can be blocked by specific amino acid sequences to inhibit capsid formation. The Bloom lab is interested in utilizing novel photochemical methods to develop improved therapeutics that interrupt the nucleocapsid-RNA interaction and reduce the infectivity of the virus

Photoredox catalysis, peptide therapeutics, biologics, targets, drug discovery, Pharma, Pharma, Bloom, Steve Bloom, The Bloom Group, KU, Science, Peptides, research, unnatural amino acids, peptide libraries, biocompatible photocatalysts, tethering biomolecules, chemotherapeutics, photochemical strategies, fusion proteins, antibody conjugates, bi-specific peptides, light activated molecules, electron oxidation, synthetic radical intermediates, therapeutic scaffolds, medicinally relevant compounds, bio-derived therapeutics, small cell lung cancer, viral capsid, improved therapeutics,
Photoredox catalysis, peptide therapeutics, biologics, targets, drug discovery, Pharma, Pharma, Bloom, Steve Bloom, The Bloom Group, KU, Science, Peptides, research, unnatural amino acids, peptide libraries, biocompatible photocatalysts, tethering biomolecules, chemotherapeutics, photochemical strategies, fusion proteins, antibody conjugates, bi-specific peptides, light activated molecules, electron oxidation, synthetic radical intermediates, therapeutic scaffolds, medicinally relevant compounds, bio-derived therapeutics, small cell lung cancer, viral capsid, improved therapeutics,

OUR RESEARCH

Photoredox catalysis, peptide therapeutics, biologics, targets, drug discovery, Pharma, Pharma, Bloom, Steve Bloom, The Bloom Group, KU, Science, Peptides, research, unnatural amino acids, peptide libraries, biocompatible photocatalysts, tethering biomolecules, chemotherapeutics, photochemical strategies, fusion proteins, antibody conjugates, bi-specific peptides, light activated molecules, electron oxidation, synthetic radical intermediates, therapeutic scaffolds, medicinally relevant compounds, bio-derived therapeutics, small cell lung cancer, viral capsid, improved therapeutics,

photoredox catalysis

View information
peptide drug discovery

peptide therapeutics

View information
Research in the Bloom lab is working towards a high-throughput strategy for inserting unnatural amino acids into peptides.

biologics

View information

Targets

View information
Photoredox catalysis, peptide therapeutics, biologics, targets, drug discovery, Pharma, Pharma, Bloom, Steve Bloom, The Bloom Group, KU, Science, Peptides, research, unnatural amino acids, peptide libraries, biocompatible photocatalysts, tethering biomolecules, chemotherapeutics, photochemical strategies, fusion proteins, antibody conjugates, bi-specific peptides, light activated molecules, electron oxidation, synthetic radical intermediates, therapeutic scaffolds, medicinally relevant compounds, bio-derived therapeutics, small cell lung cancer, viral capsid, improved therapeutics,

INTERDISCIPLINARY SCIENCE BUILDING

1567 Irving Hill road
Lawrence, Kansas 66045

1-410-459-2135

email

Instagram Twitter Youtube Facebook

© 2020 The Bloom Group / All rights reserved 

Site by TriLion